425: Glucotrack Completes Merger, Reports Pro Forma Financials

Glucotrack, Inc. has filed an amendment to its Form 8-K, providing updated pro forma financial statements reflecting its merger with Lokahi Therapeutics Inc. and a subsequent 1-for-15 reverse stock split.

Summary

• This filing is an amendment to a previous report, primarily to update pro forma financial statements following the merger between Glucotrack, Inc. and Lokahi Therapeutics Inc.
• The merger, which closed on July 14, 2026, resulted in Lokahi becoming a wholly owned subsidiary of Glucotrack.
• Pro forma financial statements combine the historical results of both companies, reflecting the merger as if it occurred on January 1, 2025, for the statement of operations and June 30, 2026, for the balance sheet.
• A 1-for-15 reverse stock split of Glucotrack's common stock became effective on August 28, 2026.
• The combined entity reported significant net losses for the periods presented: $(19,699,822) for the six months ended June 30, 2026, and $(28,135,308) for the year ended December 31, 2025.
• The merger involved the issuance of Glucotrack common and Series A convertible preferred stock to Lokahi shareholders, valuing the consideration at $33,327,384.
• Significant financing activities occurred, including bridge financings totaling approximately $7.95 million in gross proceeds and an interim PIPE of $2 million.
• The company also has a $50 million common stock purchase agreement (ELOC) with an investor, though no shares have been sold under it yet.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as negative due to the significant net losses and the dilutive nature of recent financing activities, despite the strategic merger.

Positives

• The merger with Lokahi Therapeutics Inc. has been completed, creating a combined entity.
• Pro forma financial statements are provided to give a clearer picture of the combined company's financial position and operations.
• The company has secured additional funding through bridge financings and an interim PIPE, totaling over $9.95 million in gross proceeds.
• A $50 million at-the-market equity financing facility (ELOC) is in place, providing potential future capital.

Negatives

• The combined entity reported substantial net losses: $(19,699,822) for the six months ended June 30, 2026, and $(28,135,308) for the year ended December 31, 2025.
• The merger accounting resulted in the recognition of significant intangible assets ($25.4 million) and goodwill ($14.7 million).
• Financing activities involved substantial issuance costs and day-one losses on convertible notes and warrants, impacting accumulated deficit.
• The company has a large accumulated deficit, totaling $(165,374,258) as of June 30, 2026.
• The 1-for-15 reverse stock split significantly reduces the number of outstanding shares, which can be perceived negatively by investors.

Risks

• The significant accumulated deficit and ongoing net losses pose a substantial risk to the company's financial viability.
• The substantial amount of debt and convertible notes, along with associated interest expenses and potential dilution from conversion, present financial risks.
• The recognition of significant intangible assets and goodwill carries the risk of future impairment charges if the acquired business does not perform as expected.
• The company's reliance on future financing, including the $50 million ELOC, indicates a potential need for substantial capital to fund operations and growth.

Future Outlook

The filing does not provide specific forward-looking statements or guidance beyond the details of the merger, financing transactions, and the reverse stock split. The existence of a $50 million ELOC facility suggests a need for future capital raises.

Management Comments

• The unaudited pro forma condensed combined financial information is presented for illustrative purposes only and is not necessarily indicative of what the combined company's financial position or results of operations would have been had the transaction been completed on the dates assumed.
• The unaudited pro forma condensed combined financial information is not intended to project the future financial position or operating results of the combined company following completion of the transaction.

Industry Context

StockSavvy.ai notes that the biotech/pharma industry frequently sees mergers and acquisitions to consolidate R&D efforts and market presence. The significant recognition of in-process R&D and goodwill is typical in such transactions, reflecting the valuation of future potential. However, the substantial net losses and reliance on bridge financing and ELOCs are common in early-stage or development-focused companies within this sector.

Stakeholder Impact

• Shareholders: The 1-for-15 reverse stock split will significantly reduce the number of shares held by existing shareholders, potentially impacting per-share metrics and market perception. Dilutive financing activities also pose a risk.
• Creditors: The company has taken on significant debt through bridge notes, increasing its leverage and interest expense.
• Investors: The substantial net losses and accumulated deficit may deter new investors, while existing investors face potential dilution from future capital raises.

Next Steps

• The company will continue to operate as a combined entity following the merger.
• Future capital needs may be met through the $50 million ELOC facility.
• The company will need to manage its significant net losses and operational expenses.

Key Dates

Recommendation

The merger with Lokahi Therapeutics Inc. represents a strategic step, but the significant pro forma net losses, substantial accumulated deficit, and dilutive financing activities (including bridge notes with OID and warrants, and the ELOC facility) present considerable financial risks. While the company has secured some funding, the path to profitability is unclear and burdened by high operational costs. A 'hold' recommendation reflects the uncertainty and risk associated with the company's financial trajectory, balanced against the potential of the combined entity.

Keywords

Merger, Pro Forma Financials, Reverse Stock Split, Convertible Notes, Warrants, Intangible Assets, Goodwill, Financing